机构：[1]Department of Hematology, Siping Hospital of China Medical University,Siping, Jilin 136000[2]Jilin Tuhua Bioengineering Company Ltd.,Siping, Jilin 136000[3]Department of Tissue Engineering, China Medical University, Shenyang, Liaoning 110122[4]Department of Vascular Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053血管外科首都医科大学宣武医院[5]Key Laboratory of Tissue Engineering, Siping, Jilin 136000, P.R. China
Four patients with chronic refractory immune thrombocytopenic purpura (ITP) received human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). The hUC-MSC dose was 5x10(7) to 1x10(8). Complete remission (CR) was achieved in three patients in 12 months and one patient in 24 months. Three patients received the second hUC-MSC transplantation with the same dose. The median time between hUC-MSC transplantation and response was 12.5 days (range, 7-16). There were no severe adverse events during and post hUC-MSC transplantation. During follow-up (median, 17 months; range, 13-24) no other immuno-suppressive drugs were used post-first hUC-MSCs transplantation. In conclusion, hUC-MSC transplantation is a reasonable salvage treatment in chronic refractory ITP. Prospective randomized large-scale clinical trials are needed to further elucidate the efficacy of hUC-MSCs transplantation therapy on ITP.
基金：
the National High Technology Research and Development Program, 863 Program, nos. 2011AA020101 and 2012A020905.
第一作者机构：[1]Department of Hematology, Siping Hospital of China Medical University,Siping, Jilin 136000[2]Jilin Tuhua Bioengineering Company Ltd.,Siping, Jilin 136000
通讯作者：
通讯机构：[*1]Key Laboratory of Tissue Engineering, 89 Nanyingbin Road, Siping, Jilin 136000, P.R. China[*2]Department of Vascular Surgery, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Beijing 100053, P.R. China
推荐引用方式(GB/T 7714)：
XIAOHUA WANG,XIAOGUANG YIN,WEI SUN,et al.Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up[J].EXPERIMENTAL AND THERAPEUTIC MEDICINE.2017,13(5):2255-2258.doi:10.3892/etm.2017.4229.
APA：
XIAOHUA WANG,XIAOGUANG YIN,WEI SUN,JIN BAI,YAWEN SHEN...&YING LIU.(2017).Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up.EXPERIMENTAL AND THERAPEUTIC MEDICINE,13,(5)
MLA：
XIAOHUA WANG,et al."Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up".EXPERIMENTAL AND THERAPEUTIC MEDICINE 13..5(2017):2255-2258
